close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

Benefits of SYNVISC®

In the treatment of Osteoarthritis (OA), no other viscosupplement stands up to knee pain better than SYNVISC.

Learn more about how SYNVISC provides unsurpassed pain relief and improvement in function—for up to 6 months:

  • Pain Relief—See how SYNVISC provides a large analgesic treatment effect as shown in clinical trials, and greater pain relief than a non-cross-linked product.
  • Improved Function—Review a meta-analysis demonstrating how SYNVISC provides unsurpassed improvement in patient function.
  • Duration of Pain Relief—Compare the proven duration of pain relief with 3 injections of SYNVISC to other viscosupplements.



Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)